article thumbnail

Macrocyclization via Ring-Closing Metathesis in Drug Discovery & Process Chemistry

Drug Hunter

Interestingly, among the six case studies, none use the well-known Hoveyda-Grubbs II (HG-II) catalyst in the largest scale synthesis disclosed, though several employ HG-II derivatives, highlighting the rapid evolution of catalytic methods and distinct considerations for process chemistry. Gonzalez-Bobes, F. 2023 , 66 , (8), 5377-5396.

article thumbnail

Welcome to new Director David Hulcoop

The Open Targets Blog

This involves scaling up the process of making a few grams of the compound in the lab to hundreds of tonnes in a factory, in an environmentally-friendly, cost-effective way. Process chemistry is incredibly multidisciplinary: in addition to chemists, you need analytical teams to make sure everything is 99.9%

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Metabolism of macrocyclic drugs

Metabolite Tales Blog

Current macrocycles in clinical use generally focus on treatment of infectious diseases, cancer and auto-immune disorders. A multitude of macrocyclic antiviral drugs The antiviral drug simeprevir (TMC435) was approved for the treatment of chronic hepatitis C in 2013 but has since been discontinued in favour of more effective drugs.

Drugs 52
article thumbnail

Metabolism of de novo designed macrocyclic drugs

Metabolite Tales Blog

Current macrocycles in clinical use generally focus on treatment of infectious diseases, cancer and auto-immune disorders. A multitude of macrocyclic antiviral drugs The antiviral drug simeprevir (TMC435) was approved for the treatment of chronic hepatitis C in 2013 but has since been discontinued in favour of more effective drugs.

article thumbnail

Empowering women in STEM: Navigating CMC regulatory affairs

Drug Target Review

Dr Lopa Bakrania brings over 18 years of experience in pharmaceutical process chemistry and CMC regulatory affairs. Throughout her career, Bakrania has held pivotal roles at renowned companies, including Biohaven, where she contributed to the development of therapies, such as migraine treatment Nurtec ODT.

Science 59